Evidence map›Paper›PMID 28926397›Full record

ArticleAIDS (London, England)2017

Time to first positive HIV-1 DNA PCR may differ with antiretroviral regimen in infants infected with non-B subtype HIV-1.

Raji Balasubramanian, Mary Glenn Fowler, Kenneth Dominguez, Shahin Lockman, Pat A Tookey, Nicole Ngo Giang Huong, Steven Nesheim, Michael D Hughes, Marc Lallemant, Jennifer Tosswill and 4 more

Abstract read
In one paragraph

Article in AIDS (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Raji BalasubramanianaDepartment of Biostatistics and Epidemiology, University of Massachusetts-Amherst, Amherst, Massachusetts bDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland cDivision of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia dDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston eDepartment of Immunology and Infectious Diseases, Harvard University, T. H. Chan School of Public Health, Boston, Massachusetts, USA fBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana gUniversity College Institute of Child Health, London, UK hInstitut de recherche pour le développement (IRD) UMI 174-PHPT, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand iDepartment of Biostatistics, Harvard University T. H. Chan School of Public Health, Boston, Massachusetts, USA jVirus Reference Department, National Infection Service, Public Health England, London, UK kDepartment of HIV/AIDS, World Health Organization, Geneva, Switzerland lDepartment of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand and National Institute for Communicable Diseases, Johannesburg, South Africa mSection of Infectious Diseases and International Health, Geisel School of Medicine at Dartmouth, 1 Medical Center Dr, Lebanon, New Hampshire nCenter for Biostatistics in AIDS Research, Harvard University T. H. Chan School of Public Health. Boston, Massachusetts, USA.
Mary Glenn Fowler
Kenneth Dominguez
Shahin Lockman
Pat A Tookey
Nicole Ngo Giang Huong
Steven Nesheim
Michael D Hughes
Marc Lallemant
Jennifer Tosswill
Nathan Shaffer
Gayle Sherman
Paul Palumbo
David E Shapiro

Funding

PREVENTION OF MILK-BORNE TRANSMISSION OF HIV IN BOTSWANAR01HD037793 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 2000 to 2004
$6.9M
NEVIRAPINE+ZIDOVUDINE--PREVENT PERINATAL HIV IN THAILANDR01HD039615 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI LALLEMANT, MARC J · 2000 to 2002
$3.7M
Properties of HIV-1 DNA/RNA Assays for Detecting HIV Infection in InfantsR21HD072792 · NICHD · UNIVERSITY OF MASSACHUSETTS AMHERST · PI BALASUBRAMANIAN, RAJI · 2011 to 2012
$458k
SHORT ZDV COURSE TO PREVENT PERINATAL HIV IN THAILANDR01HD033326 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI LALLEMANT, MARC J · 1996 to 2000
$368k
NICHD NIH HHS R01 HD033326NICHD NIH HHS R01 HD037793NICHD NIH HHS R01 HD039615NICHD NIH HHS R21 HD072792World Health Organization 001
6 · The paper itself

Abstract

objectiveTo evaluate the association of type and timing of prophylactic maternal and infant antiretroviral regimen with time to first positive HIV-1 DNA PCR test, in nonbreastfed HIV-infected infants, from populations infected predominantly with HIV-1 non-B subtype virus.

designAnalysis of combined data on nonbreastfed HIV-infected infants from prospective cohorts in Botswana, Thailand, and the United Kingdom (N = 405).

methodsParametric models appropriate for interval-censored outcomes estimated the time to first positive PCR according to maternal or infant antiretroviral regimen category and timing of maternal antiretroviral initiation, with adjustment for covariates.

resultsMaternal antiretroviral regimens included: no antiretrovirals (n = 138), single-nucleoside analog reverse transcriptase inhibitor (n = 165), single-dose nevirapine with zidovudine (n = 66), and combination prophylaxis with 3 or more antiretrovirals [combination antiretroviral therapy (cART), n = 36]. Type of maternal/infant antiretroviral regimen and timing of maternal antiretroviral initiation were each significantly associated with time to first positive PCR (multivariate P < 0.0001). The probability of a positive test with no antiretrovirals compared with the other regimen/timing groups was significantly lower at 1 day after birth, but did not differ significantly after age 14 days. In a subgroup of 143 infants testing negative at birth, infant cART was significantly associated with longer time to first positive test (multivariate P = 0.04).

conclusionTime to first positive HIV-1 DNA PCR in HIV-1-infected nonbreastfed infants (non-B HIV subtype) may differ according to maternal/infant antiretroviral regimen and may be longer with infant cART, which may have implications for scheduling infant HIV PCR-diagnostic testing and confirming final infant HIV status.

Indexed as

GenotypeAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveBotswanaChemopreventionDNA, ViralFemaleHIV-1HIV InfectionsHumansInfantInfant, NewbornMalePolymerase Chain ReactionPregnancyProspective StudiesAnti-Retroviral AgentsDNA, Viral

Identifiers

PMID28926397
PMCPMC5710822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.